Loading clinical trials...
Loading clinical trials...
A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Conditions
Interventions
Vorinostat
Pegylated Liposomal Doxorubicin (PLD), Doxil
Locations
1
United States
Yale University School of Medicine
New Haven, Connecticut, United States
Start Date
January 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
April 4, 2022
Lead Sponsor
Yale University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions